Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS/FDA Ephedra Strategy: A Risk Management Approach?

This article was originally published in The Tan Sheet

Executive Summary

HHS Secretary Tommy Thompson is urging manufacturers of ephedrine alkaloid supplements to include FDA's MedWatch toll-free number on labeling to better enable consumer reporting of adverse events
Advertisement

Related Content

Ephedra Product Liability Coverage Now Offered By Fewer Than 10 Insurers
Ephedra Product Liability Coverage Now Offered By Fewer Than 10 Insurers
Ephedra Product Liability Coverage Now Offered By Fewer Than 10 Insurers
Ephedra “Imminent Hazard” Declaration Sought By Sen. Durbin
Three-Step Supplement Safety Review Model Proposed by IoM
USP Ephedra Review Scheduled For July; RAND Report Slated For Early Fall
E’Ola Ephedrine Hydrochloride Sales Barred Under FDA Settlement
E’Ola Ephedrine HCl Product Seized, FDA Complaint Alleges Item To Be Drug
E’Ola Ephedrine HCl Product Seized, FDA Complaint Alleges Item To Be Drug
AHRQ Ephedra Evidence Report Targeted For August 2002 Release

Topics

Advertisement
UsernamePublicRestriction

Register

PS094152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel